Dr. Aparna Kamat - Oncologist in ...

Dr. Aparna Kamat, MD

Claim this profile

Houston Methodist Sugar Land Hospital

Studies Ovarian Cancer
Studies Fallopian Tube Cancer
7 reported clinical trials
18 drugs studied

Area of expertise

1

Ovarian Cancer

Aparna Kamat, MD has run 5 trials for Ovarian Cancer. Some of their research focus areas include:

Stage IV
AKT positive
BRCA1 positive
2

Fallopian Tube Cancer

Aparna Kamat, MD has run 2 trials for Fallopian Tube Cancer. Some of their research focus areas include:

Stage III
Stage II
Stage IV

Affiliated Hospitals

Image of trial facility.

Houston Methodist Sugar Land Hospital

Image of trial facility.

Methodist Willowbrook Hospital

Clinical Trials Aparna Kamat, MD is currently running

Image of trial facility.

Avutometinib + Defactinib

for Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Recruiting

2 awards

Phase 3

8 criteria

Image of trial facility.

Herceptin Hylecta or Phesgo + Chemotherapy

for Uterine Cancer

This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.

Recruiting

2 awards

Phase 3

More about Aparna Kamat, MD

Clinical Trial Related

8 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Aparna Kamat, MD has experience with

  • Paclitaxel
  • Afuresertib
  • Ribociclib
  • Letrozole
  • InterVenn Ovarian Cancer Liquid Biopsy
  • Defactinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Aparna Kamat, MD specialize in?

Is Aparna Kamat, MD currently recruiting for clinical trials?

Are there any treatments that Aparna Kamat, MD has studied deeply?

What is the best way to schedule an appointment with Aparna Kamat, MD?

What is the office address of Aparna Kamat, MD?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security